Amivantamab Shows Promise in Challenging EGFR-Mutated NSCLC Amivantamab Shows Promise in Challenging EGFR-Mutated NSCLC

The novel drug appears to be effective for patients with EGFR-mutated NSCLC that has a hard-to-treat exon 20 insertion after disease progression with platinum-based chemotherapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news